Experts discuss how obstetric and pediatric clinicians can coordinate to protect newborns.
|Articles|June 28, 2021
This week on Contemporary OB/GYN®: June 28 to July 2
Author(s)Contemporary OB/GYN Staff
Here's what to expect this week from Contemporary OB/GYN®.
Advertisement
You can expect coverage of various topics this week on Contemporary OB/GYN®, including:
The diagnosis and treatment of neonatal hypoglycemia
Long-term outcomes of neonatal hypoglycemia
New diversity policy from AMA
In this issue
Check back soon for the live articles and additional updates.
Advertisement
Related to this article
Experts review ACOG's 2026-27 guidance and the RSV window extension for pregnant and postpartum patients.
Soma Mandal, MD, is launching “Mind, Body, & the Pause: the Perimenopause and Beyond Series” on Contemporary OB/GYN, featuring specialists from across Hackensack Meridian Health.
On September 9, 2026, certolizumab pegol received FDA Breakthrough Therapy Designation for APS pregnancy; Jane E. Salmon, MD, reviews the IMPACT trial results behind it.
Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.
SUID was the largest single contributor to the Black-White infant mortality gap in 2024 and drove the biggest share of its rise since 2020.
Garima Sharma, MD, outlines validated cardiac risk scores for antenatal screening and the postpartum transitions needed to keep high-risk patients from being lost to follow-up.
Anti-CGRP antibody exposure in early pregnancy was linked to higher spontaneous abortion risk; propranolol was not.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Jane E. Salmon, MD, on the IMPACT trial of certolizumab pegol for adverse pregnancy outcomes in APS
2
SUID drives widening Black-White infant mortality gap since 2020
3
Psychotherapy in menopause care: Addressing fear, anxiety, and GSM
4
Anti-CGRP antibodies associated with higher spontaneous abortion risk
5